Showing 7441-7450 of 10277 results for "".
- FDA Accepts NDA for Allergan, Paratek Acne Drughttps://practicaldermatology.com/news/fda-accepts-nda-for-allergan-paratek-acne-drug/2457946/The U.S. Food and Drug Administration accepted a New Drug Application (NDA) to review SeysaraTM(sarecycline) for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older, Allergan plc and Parate
- Aclaris Initiates Pilot Clinical Trial of ATI-50002 Topical for Vitiligohttps://practicaldermatology.com/news/aclaris-initiates-pilot-clinical-trial-of-ati-50002-topical-for-vitiligo/2457947/Aclaris Therapeutics, Inc., has initiated a Phase 2 open-label clinical trial of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002 Topical) and an investigational drug, for the potential treatment of non-segmental vitiligo of the face. This trial will evaluate the safety, t
- Biofrontera Files Investigational NDA for Phase 3 Trial of Ameluz for BCChttps://practicaldermatology.com/news/biofrontera-files-investigational-nda-for-phase-3-trial-of-ameluz-for-bcc/2457948/Biofrontera AG has filed an investigational new drug (IND) application with the FDA for its proposed Phase 3 study protocol to evaluate Ameluz® photodynamic therapy (PDT) for the treatment of superficial basal cell carcinoma. The IND filing is in accordance with the advice provided by F
- NPF Launches New Resource for Youth with Psoriasis, Psoriatic Arthritishttps://practicaldermatology.com/news/npf-launches-new-resource-for-youth-with-psoriasis-psoriatic-arthritis/2457949/Our Spot, a new resource launched by The National Psoriasis Foundation (NPF), provides resources for kids and teens living with psoriasis and psoriatic arthritis. The program includes a
- Study: Minorities Less Likely to See a Doctor for Psoriasishttps://practicaldermatology.com/news/study-minorities-less-likely-to-see-a-doctor-for-psoriasis/2457954/Minorities are less likely than white Americans to see a doctor for psoriasis treatment despite the fact that their disease may be more severe, a new study shows. Researchers from the Perelman School of Medicine at the University of Pennsylvania fou
- Understanding the Role of Long Strands of RNA in Skin Development, Diseasehttps://practicaldermatology.com/news/understanding-the-role-of-long-strands-of-rna-in-skin-development-disease/2457958/RNA pieces, called “long non-coding RNAs” or “lncRNAs,” help skin cells modulate connective tissue proteins, like collagen, and could represent novel therapeutic targets to promote skin repair, according to researchers from Case Western Reserve University School of Medicin
- Revance: RT002 Achieves 6-Month Duration in Phase 3https://practicaldermatology.com/news/revance-rt002-achieves-6-month-duration-in-phase-3/2457959/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared ge
- Gene Expressions May Be Key to More Youthful Looking Skinhttps://practicaldermatology.com/news/gene-expressions-may-be-key-to-more-youthful-looking-skin/2457962/Some individuals’ skin appears more youthful than their chronologic age, and now new research indicates that increased expression of certain genes may be the key to intrinsically younger looking — and younger behaving — skin. The findings appear in the
- Milestone Scientific Set To Launch New Botox Delivery Instrumenthttps://practicaldermatology.com/news/milestone-scientific-set-to-launch-new-botox-delivery-instrument/2457965/Botulinum toxin injections may be about to get smarter and more comfortable as Milestone Scientific Inc. gears up to launch its novel and proprietary cosmetic injection instrument. The new cosmetic injection instrument allows the clinician
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of